Royalty Pharma logo

Royalty PharmaNASDAQ: RPRX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 June 2020

Next earnings report:

06 November 2024

Last dividends:

16 August 2024

Next dividends:

15 November 2024
$12.23 B
-37%vs. 3y high
94%vs. sector
-93%vs. 3y high
32%vs. sector
-43%vs. 3y high
55%vs. sector
-37%vs. 3y high
63%vs. sector

Price

after hours | Fri, 01 Nov 2024 22:36:51 GMT
$27.29+$0.26(+0.96%)
$537.27 M$696.10 M
$537.27 M$102.00 M

Analysts recommendations

Institutional Ownership

RPRX Latest News

Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics
zacks.com01 November 2024 Sentiment: POSITIVE

Beyond analysts' top -and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
globenewswire.com16 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day.

Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
zacks.com14 October 2024 Sentiment: POSITIVE

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Royalty Pharma Declares Fourth Quarter 2024 Dividend
globenewswire.com11 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share.

What Makes Royalty Pharma (RPRX) a New Buy Stock
zacks.com08 October 2024 Sentiment: POSITIVE

Royalty Pharma (RPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 No-Brainer Dividend Stocks to Buy With $100 in October
fool.com01 October 2024 Sentiment: POSITIVE

With their high yields and strong underlying businesses, these stocks are hard to pass up.

2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now?
fool.com28 September 2024 Sentiment: POSITIVE

At less than 8 times trailing earnings, Western Union looks like a bargain. Royalty Pharma could grow its specialty financing business much faster than its recent valuation suggests.

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
globenewswire.com03 September 2024 Sentiment: POSITIVE

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
seekingalpha.com22 August 2024 Sentiment: POSITIVE

Vertex franchise poses a significant downside risk. That said, Royalty Pharma has solid execution capabilities and is diversifying earnings with new investments. The company raised its 2024 outlook after three quarters of double-digit growth. A solid team, a balance sheet with M&A maneuvers, and an impressive track record make the company a buy.

Royalty Pharma: Busy Putting Capital To Work
seekingalpha.com11 August 2024 Sentiment: POSITIVE

Royalty Pharma's stock has underperformed recently, down 7% year to date while the S&P500 has climbed 13%. In the company's latest Q2'24 results, Royalty Pharma reported a 12% increase in portfolio receipts, driven by sales growth from its cystic fibrosis franchise and other drugs. The company has also been active in acquiring new royalties and investing in various therapeutic areas and is on track to exceed deployment targets.

  • 1(current)
  • 2

What type of business is Royalty Pharma?

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

What sector is Royalty Pharma in?

Royalty Pharma is in the Healthcare sector

What industry is Royalty Pharma in?

Royalty Pharma is in the Biotechnology industry

What country is Royalty Pharma from?

Royalty Pharma is headquartered in United States

When did Royalty Pharma go public?

Royalty Pharma initial public offering (IPO) was on 16 June 2020

What is Royalty Pharma website?

https://www.royaltypharma.com

Is Royalty Pharma in the S&P 500?

No, Royalty Pharma is not included in the S&P 500 index

Is Royalty Pharma in the NASDAQ 100?

No, Royalty Pharma is not included in the NASDAQ 100 index

Is Royalty Pharma in the Dow Jones?

No, Royalty Pharma is not included in the Dow Jones index

When was Royalty Pharma the previous earnings report?

No data

When does Royalty Pharma earnings report?

The next expected earnings date for Royalty Pharma is 06 November 2024